Similar companies
Income Statement (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Revenue | 47M | 3.9% |
| Gross Profit | 25M | 10.5% |
| Cost of Revenue | 21M | 3% |
| Operating expense | 34M | 0.6% |
| Net Income | -10M | 69.1% |
| EBITDA | -7.6M | 0.3% |
Balance Sheet (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 484M | 1.7% |
| Total Liabilities | 95M | 4.9% |
| Total Equity | 389M | 0.9% |
| Shares Outstanding | 132M | 0.2% |
Cash Flow (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | 6.2M | 56.8% |
| Cash from investing | 2M | 135.1% |
| Cash from financing | -1.7M | 206.1% |
EPS
Financial Highlights for Cytek BioSciences in Q2 '24
Cytek BioSciences reported a revenue of 47M, which is a 3.9% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 25M, marking a 10.5% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 21M, a -3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 34M, showing a 0.6% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -10M, showing a -69.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -7.6M, showing a 0.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Cytek BioSciences faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
